Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Report
|
Despite ongoing competition from biosimilars, branded biologics will continue to drive the Chinese autoimmune market, with two new brands, Enbrel (etanercept; Pfizer) and Humira (adalimumab; Abbott), having been approved and launched in 2010.
Published By Datamonitor
|
14 Sep 2011 |
$5700
|
Report
|
The launch and uptake of biologics has grown across India – primarily in urban areas – but affordability is a major limiting factor, thereby providing an opportunity for the pharmaceutical companies manufacturing cost-effective biosimilars.
Published By Datamonitor
|
25 Aug 2011 |
$5700
|
Brief
|
This brief is an overview of the HCV highlights from the 2010 American Association of the Study of Liver Disease meeting. It discusses pivotal data for telaprevir and boceprevir, results for TMC435 and data from interferon-sparing studies.
Published By Datamonitor
|
13 Dec 2010 |
$500
|
Report
|
Physician survey of 84 endocrinologists and primary care physicians on their impressions and expected use of Amylin’s and Alkermes’s Bydureon (once-weekly exenatide)
Published By Datamonitor
|
24 Feb 2012 |
$3800
|
Report
|
The large number of Chinese CV & metabolic diseases patients brings significant commercial opportunities for Pharma. Plans to expand insurance coverage and improve healthcare infrastructure will enhance therapy access, boosting the market potential.
Published By Datamonitor
|
09 Dec 2011 |
$5700
|
Report
|
This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway.
Published By Datamonitor
|
16 Apr 2012 |
$1900
|
Report
|
This module discusses differential pricing for antiretrovirals as a strategy that enhances access to drugs while preserving incentives for pharmaceutical companies.
Published By Datamonitor
|
18 May 2011 |
$1900
|
Report
|
Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies.
Published By Datamonitor
|
16 Jul 2012 |
$1900
|
Report
|
The Surviving Sepsis Campaign has created an increased focus on reducing levels of mortality from sepsis. Eli Lilly/BioCritica’s Xigris has been unable to capitalize on what remains a potentially lucrative therapy area with significant unmet needs.
Published By Datamonitor
|
17 May 2011 |
$1900
|
Report
|
CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel CNS treatments is to remain commercially viable.
Published By Datamonitor
|
05 Sep 2012 |
$3800
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.